临床淋巴结阳性乳腺癌患者新辅助全身治疗后腋窝淋巴结反应的专用腋窝混合18F-FDG PET/MRI研究:一项先导研究
这项先导研究前瞻性纳入10例临床淋巴结阳性乳腺癌患者,在新辅助全身治疗后行专用腋窝混合18F-FDG PET/MRI检查,以腋窝手术标本病理为参考标准,按患者和按淋巴结分析诊断效能。6例患者达到腋窝病理完全缓解,共匹配84枚淋巴结,其中10枚有残留病变。按患者分析敏感度25%、特异度100%、阳性预测值100%、阴性预测值67%;按淋巴结分析分别为0%、96%、0%、88%。结论认为专用腋窝18F-FDG PET/MRI的阴性预测值和敏感度不足以准确检测腋窝病理完全缓解或排除残留腋窝病变。
要点
- 按患者分析敏感度仅25%,阴性预测值67%,不足以排除残留腋窝病变。
- 按淋巴结分析敏感度0%,排除微转移后阴性预测值由88%升至90%。
- 特异度和阳性预测值按患者分析均为100%,但阳性病例数有限。
核心结论
- 这项先导研究提示,专用腋窝18F-FDG PET/MRI的阴性预测值和敏感度不足以准确检测临床淋巴结阳性乳腺癌患者新辅助全身治疗后的腋窝病理完全缓解或排除残留腋窝病变。
研究设计与样本
- 前瞻性纳入10例临床淋巴结阳性乳腺癌患者,在新辅助全身治疗后完成专用腋窝混合18F-FDG PET/MRI检查,随后行腋窝手术。
- PET图像由核医学医师审阅,冠状位T1加权和T2加权MRI图像由放射科医师审阅。
- PET/MRI上可见的所有腋窝淋巴结与腋窝手术切除的淋巴结进行匹配,以腋窝手术标本的组织病理学为参考标准。
- 基于患者逐一和淋巴结逐一验证计算诊断效能参数。
诊断标准与关键数值
- 按患者分析:敏感度25%、特异度100%、阳性预测值100%、阴性预测值67%。
- 按淋巴结分析:敏感度0%、特异度96%、阳性预测值0%、阴性预测值88%。
- 按淋巴结分析排除微转移后,阴性预测值提高至90%。
- 组织病理学显示,匹配的腋窝淋巴结中10枚有残留腋窝病变,其中8枚为大转移、2枚为微转移。
临床应用与阅片要点
- 原文结论认为该方法的阴性预测值和敏感度不足以准确检测腋窝病理完全缓解或排除残留腋窝病变。
局限性
- 原文结论将本研究限定为先导研究,并指出专用腋窝18F-FDG PET/MRI的阴性预测值和敏感度不足以准确检测腋窝病理完全缓解或排除残留腋窝病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To investigate the diagnostic performance of dedicated axillary hybrid 18F-2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting axillary pathological complete response (pCR) following neoadjuvant systemic therapy (NST) in clinically node-positive breast cancer patients.
MATERIALS AND METHODS: Ten prospectively included clinically node-positive breast cancer patients underwent dedicated axillary hybrid 18F-FDG PET/MRI after completing NST followed by axillary surgery. PET images were reviewed by a nuclear medicine physician and coronal T1-weighted and T2-weighted MRI images by a radiologist. All axillary lymph nodes visible on PET/MRI were matched with those removed during axillary surgery. Diagnostic performance parameters were calculated based on patient-by-patient and node-by-node validation with histopathology of the axillary surgical specimen as the reference standard.
RESULTS: Six patients achieved axillary pCR at final histopathology. A total of 84 surgically harvested axillary lymph nodes were matched with axillary lymph nodes depicted on PET/MRI. Histopathological examination of the matched axillary lymph nodes resulted in 10 lymph nodes with residual axillary disease of which eight contained macrometastases and two micrometastases. The patient-by-patient analysis yielded a sensitivity, specificity, positive predictive value, and negative predictive value of 25%, 100%, 100%, and 67%, respectively. The diagnostic performance parameters of the node-by-node analysis were 0%, 96%, 0%, and 88%, respectively. Excluding micrometastases from the node-by-node analysis increased the negative predictive value to 90%.
CONCLUSION: This pilot study suggests that the negative predictive value and sensitivity of dedicated axillary 18F-FDG PET/MRI are insufficiently accurate to detect axillary pCR or exclude residual axillary disease following NST in clinically node-positive breast cancer patients.
引用
- de Mooij, Samiei, Mitea, et al. Axillary lymph node response to neoadjuvant systemic therapy with dedicated axillary hybrid 18F-FDG PET/MRI in clinically node-positive breast cancer patients: a pilot study. Clin Radiol. 2022. PMID: 35850866. doi:10.1016/j.crad.2022.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。